drugset / Trial / NCT00828672
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated. To assess the activity of bevacizumab (AvastinTM) in combination with capecitabine (XelodaTM) and radiation therapy with or without oxaliplatin (EloxatinTM) in the pre-operative treatment of locally advanced rectal cancer, followed by TME (total mesorectal excision).
Timeline
- Start
- 2009-06
- Primary completion
- 2014-03
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Comparator | Capecitabine | Small molecule | 825 mg/m2 | — |
| Comparator | Oxaliplatin | Small molecule | 50 mg/m2 | — |
Indications
No indication recorded.